Currently, Drug Counterfeiting is the biggest challenge facing the pharmaceutical industry. They are encountering this threat due to high market demand for the drugs and their profit margin. The lack of data transparency and traceability also lured criminals into the counterfeiting of drugs which, is impacting people’s health and put their life in danger. Through the drug supply chain, a substantial portion of counterfeit drugs are injected and distributed through the healthcare supply chain network, so the supply chain plays a vital role in drug distribution and impacts patient lives. Through digitalization in the healthcare sector, Distributed Ledger Technology (DLT) provides a platform with ground-breaking results by providing a system for drug traceability with consideration of the critical requirements of transparency, privacy, and authenticity without involving any third party. In DLT, each distribution partner is registered to maintain transparency with the drug information. Real-time transfer of information about the change of ownership with date and time in the form of blocks gives visibility to all the partners in real time about the authenticity of drugs. This article will give information about the benefits of Distributed Ledger Technology to the pharmaceutical industry and the traceability of drugs from end-to-end of the pharmaceutical supply chain.

This work details how the integration of cloud computing and advanced data engineering can innovate and reshape patient care and digital infrastructure. In the healthcare sector, cloud services offer the necessary support to generate digitally-oriented services and service kits. These services can contain high levels of availability, low levels of latency, and on-demand scaling capabilities, while following the strictest data protection laws and regulations. On the other hand, these services can be combined with data engineering techniques to construct an ecosystem that enhances and adds an optimized data layer on any cloud environment. This ecosystem includes technologies to acquire, process, and manage healthcare data while respecting all regulatory obligations and institutions and can be part of a comprehensive digitalization strategy. The objective is to augment the healthcare services that the industry offers by leveraging healthcare data and AI technologies. Designed services, processes, and technologies can be described either as industry-agnostic services or healthcare-specific services that process and manage electronic healthcare records (EHR). Industry-agnostic services offer a set of tools and methodologies to conduct optimized data experiments. The goal is to exploit any variety, velocity, volume, and veracity of medical data. Healthcare-specific services offer a set of tools and methodologies to connect to any common EHR vendor in a privacy-preserving manner. Participating companies are thus able to hold, share, and make use of healthcare data in real-time. The proposed architecture can be transformative for the healthcare industry, opening up and facilitating experimentation on new and scalable service models. The transition to a more digital health approach would help overcome the limits encountered in traditional settings. Limitations in the availability of healthcare facilities and healthcare professionals have underpinned the increasing share of telemedicine in the care process. However, the record-keeping of the patients that undergo care outside of traditional healthcare facilities is often missing and can severely influence the continuity of treatment. Identifying new methods to implement disease prevention and early intervention processes is crucial to avoid more extensive treatment and to support those on multiple line therapies. For chronic patients, having a service available that monitors the state of health and intervenes when parameters go off the wanted range is crucial. However, the same patients are the most under the influence of the decision of care providers; a second opinion might be given remotely which the patient can access at any time on-demand. To address these different kinds of services, an ecosystem composed of a dictionary's worth data layer is outlined, able to live and operate seamlessly in any cloud environment. This future work's envisioned outcome is the rapid evolution and re-definition of the European healthcare landscape.

This essay explores how AI can enhance clinical research and, particularly, its pivotal role in the development of medical devices. A data-driven approach to medical device development that can streamline regulatory compliance and quality assurance is discussed. Methods that generate insights from pre-stage data and utilize it during development are detailed. The effectiveness of this approach in compliance audits, 510(k) submissions, and quality system audits - reducing time, effort, and risks is analyzed. The findings are illustrated with practical examples and takeaway recommendations. When reading a scientific article, how many times have you judged the quality of the research by looking at the methodology section? Artificial intelligence algorithms can be developed with the most robust and innovative technology, but if they are not properly validated, they will be worthless in the eyes of regulatory authorities. Conversely, outdated and simplistic models can still gain regulatory clearance if robustness is effectively demonstrated. For better or worse, ethics, economics, and robustness are often sacrificed in the constant government struggle to keep up with the technological edge of AI development. The slow crawl of lawmakers is constant in every field. Automating small tasks can save time and reduce risks when playing catch-up with a changing regulatory framework so the rest of the AI development can continue uninhibitedly. This dives into using FDA open data to collaborate with a food and drug law company and develop several bottom-up initiatives that supply knowledge needed for regulatory compliance and quality systems development. Methods that input pre-stage data and output actionable insights as models are provided. By sharing these resources and advice as academic researchers, efficiency in streamlining processes is maximized, thereby letting more time and resources be allocated to the actual development [1].